Reflections on Progress and Partnership at ASCO 2026
Research news from ASCO 2026 highlights progress in RAS-targeted oncology and ongoing efforts to streamline US clinical trial activation. In an NCI Director commentary dated June 16, 2026, Dr. Anthony Letai described a plenary phase III presentation reporting that daraxonrasib, a RAS(on) inhibitor, nearly doubled median overall survival versus chemotherapy in previously treated advanced pancreatic cancer, while noting remaining uncertainties about safety. He also summarized stakeholder discussions, including an FDA-hosted panel, on reducing operational inefficiencies that delay trial activation.
Reflections on Progress and Partnership at ASCO 2026 (research news)
In a June 16, 2026 commentary following the ASCO Annual Meeting (Chicago, May 29–June 2), NCI Director Anthony Letai, MD, PhD, highlighted themes of accelerating scientific progress and improving clinical trial execution.
Pancreatic cancer/RAS-targeted therapy: Letai referenced a plenary presentation by Brian Wolpin, MD, reporting phase III trial results in previously treated, advanced pancreatic cancer, in which daraxonrasib (described as a RAS(on) inhibitor) nearly doubled median overall survival compared with chemotherapy. Letai noted that “there is still much to learn about the drug and its side effects,” indicating ongoing uncertainty about toxicity and broader clinical implications.
Scientific context: The commentary linked this advance to decades of RAS biology and drug discovery, noting that >90% of pancreatic cancers and ~30% of all human cancers are driven by RAS gene changes, and citing NCI-supported work (e.g., discovery of a KRAS G12C pocket and the NCI RAS Initiative) that helped catalyze development of RAS inhibitors.
Clinical trial activation: Letai described participating in stakeholder sessions—including a public FDA-hosted panel—focused on accelerating US trial activation by addressing operational inefficiencies (e.g., simplifying trial designs and standardizing contracts) while maintaining patient safety and scientific rigor.
No regulatory approval information was reported in the source.